Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612456 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00612456 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 70 participants.
The verdict
NCT00612456, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-03-05 |
| Est. Completion | 2009-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612456
The ClinicalTrials.gov registry entry for NCT00612456 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT00612456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612456 about?
NCT00612456 is a clinical study titled "To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD". This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
What is the current status of trial NCT00612456?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2008-03-05. Estimated completion is 2009-06-17.
What interventions are being tested in trial NCT00612456?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00612456?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.